Prior to establishing Janssen Partners, Inc., Peter Janssen raised capital for and/or provided Investment Banking services to:

MacroChem Corporation, Inc.
www.macrochem.com

MacroChem Corporation [Nasdaq: MCHM] is a drug delivery company that develops treatments for major diseases based on a patented absorption-enhancement technology called SEPA®. SEPA (soft enhancement of Percutaneous Absorption) promoted topical absorption of drugs through the skin. Such technology can enhance patient care and convenience, and reduce the risk of systemic side effects, as compared to ordinary oral and injected versions of those same drugs.